Governance, Compliance & Audit Readiness
Zero non-compliant audits across five countries. We build governance frameworks that hold under regulatory scrutiny.
- 0
- Non-compliant IT audits across 5 countries over 3 years
- 100%
- MLPS cybersecurity certification for Bayer China services
- BIG 4
- Audit transition management with PwC, Deloitte, EY
- GxP
- Pharma quality management across commercial operations
Overview
About this practice
Governance failures are expensive. A significant audit finding in a regulated industry does not just cost remediation time — it costs management credibility, regulatory relationships, and in pharma, it can cost product approvals. The organisations that avoid this are not lucky. They are designed differently.
Talvoren Advisory builds governance frameworks that are proactive, not reactive. Peter Gent implemented global compliance frameworks, managed external audit transitions with Big 4 firms, and designed internal controls across complex multi-entity structures in pharma, industrials, and chemicals. Mikhail Konovalov built specialised task-force teams at Bayer that executed compliance reboots under regulatory pressure — achieving zero non-compliant IT audits across Russia, Kazakhstan, Belarus, and China simultaneously, reducing significant and moderate audit findings to zero.
Our approach is structured, documented, and measurable. We define the controls, build the monitoring processes, and leave behind an organisation that can sustain compliance independently — not one that is dependent on external advisors to pass its next audit.
Key Benefits
What you get
-
Internal controls assessment: gap analysis against your regulatory framework (SOX, DSGVO, MLPS, pharma GxP)
-
Audit readiness programme: structured preparation for Big 4 external audits, regulatory inspections, or PE due diligence
-
IT controls and cybersecurity governance: security mapping, proactive controls, and ongoing monitoring frameworks
-
Global tax compliance: transfer pricing documentation, country-by-country reporting, and BEPS compliance
-
External audit partner selection and transition management
-
Risk management in regulated markets: pharma GxP, chemicals REACH, financial services controls
-
Compliance task-force deployment for organisations facing significant or critical audit findings
Who This Is For
Built for
organizations like yours
This practice area is designed for organizations facing the challenges listed here. If your situation matches, we should talk.
-
Pharma companies facing GxP audit findings or regulatory inspections
-
Multinationals in China, Russia, or CIS needing compliance frameworks
-
Companies under PE due diligence needing audit-ready governance
-
CFOs seeking independent governance review ahead of IPO or M&A
Also in Our Portfolio
GBS Design & Build
We design and build GBS organisations from first principles — CFO rigour, operational experience, measurable results.
Learn moreFinance Function Transformation
End-to-end redesign of the finance operating model — from reporting architecture to business partnering capability.
Learn moreAsia & Emerging Market Operations Advisory
On-the-ground expertise in China, Japan, and Russia — markets where standard Western playbooks fail.
Learn moreStart Here
Start a conversation
Tell us about your challenge. We'll share our perspective — no obligation, no boilerplate proposal.